Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)ReceivablesShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sanofi (SNY) Assets (2016 - 2025)

Sanofi (SNY) has disclosed Assets for 9 consecutive years, with $147.6 billion as the latest value for Q4 2025.

  • Quarterly Assets rose 4.02% to $147.6 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $554.9 billion through Dec 2025, up 36.24% year-over-year, with the annual reading at $143.3 billion for FY2025, 0.32% changed from the prior year.
  • Assets hit $147.6 billion in Q4 2025 for Sanofi, up from $141.9 billion in the prior quarter.
  • In the past five years, Assets ranged from a high of $147.6 billion in Q4 2025 to a low of $129.3 billion in Q4 2022.
  • Historically, Assets has averaged $138.7 billion across 4 years, with a median of $139.0 billion in 2023.
  • Biggest five-year swings in Assets: rose 5.24% in 2023 and later increased 4.02% in 2025.
  • Year by year, Assets stood at $129.3 billion in 2022, then increased by 5.24% to $136.1 billion in 2023, then grew by 4.29% to $141.9 billion in 2024, then rose by 4.02% to $147.6 billion in 2025.
  • Business Quant data shows Assets for SNY at $147.6 billion in Q4 2025, $141.9 billion in Q4 2024, and $136.1 billion in Q4 2023.